Atrauman Ag in the treatment of chronic wounds - An application study on 624 patients;Die silberhaltige salbenkompresse Atrauman Ag bei der behandlung chronischer wunden: Anwendungsbeobachtung mit 624 patienten

Aktuelle Dermatologie

Volumn 31, Issue 12, 2005, Pages 561-565

  Zoellner, P ^a   Kapp, Holger ^a   Smola, H ^a,b  

^a Paul Hartmann AG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; FUSIDIC ACID; SILVER;

AGED; ARTICLE; CHRONIC WOUND; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; EPITHELIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; SAMPLE SIZE; TREATMENT OUTCOME; WOUND DRESSING; WOUND FLUID; WOUND HEALING;

EID: 29244441707     PISSN: 03402541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870541     Document Type: Article

References (18)

1. Gillitzer R. Modernes Wundmanagement. Hautarzt 2002;53: 130-147
2. Hess CT, Kirsner RS. Orchestrating wound healing: Assessing and preparing the wound bed. Adv Skin Wound Care 2003;16:246-259
3. Sibbald RG, Heather O, Schultz GS, Coutts P, Keast D. Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage 2003;49:24-51
4. Mulligan S, Denman S, Bennett RG, Greenough WB, Lindsay J, Zelesnick LB. Methicillin-resistant Staphylococcus aureus colonization in a long term-care facility. J Am Geriatr Soc 1992;40:213-217
5. Scheithauer M, Riechelmann H. Die gestörte kutane Wundheilung. Laryngo-Rhino-Otol 2003;82:36-39
6. Bowler PG, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001;14:244-269
7. Mulligan CM, Bragg AJ, OToole OB. A controlled comparative trail of Actisorb activated charcoal cloth dressings in the community. Br J Clin Pract 1986;40:145-148
8. Lansdown A. A review of the use of silver in wound care: facts and fallacies. Br J Nurs 2004;13:S6-S19
9. Dunn K, Edwards-Jones V. The role of Acticoat with nanocristalline silver in the management of burns. Burns 2004;30:Sl-S9
10. Stadler R, Wallenfang K. Anwendungsbeobachtung der aktivkohlehaltigen Wundauflage Actisorb bei 12444 Patienten mit chronischen Wunden. Akt Dermatol 2002;28:351-354
11. Percival SL, Bowler PG, Russel D. Bacterial resistance to silver in wound care. J Hospital Infect 2005; 60:1-7
12. McCauley RI, Linares HA, Pelligrini V, Herndon DN, Robson MC, Heggers JP. In vitro toxicity of topical antimicrobial agents to human fibroblasts. J Surg Res 1989;46:267-274
13. Bowler PG, Davies BJ. The microbiology of infected and noninfected leg ulcers. Int J Dermatol 1999;38: 573-578
14. Edwards R, Harding KG. Bacteria and wound healing. Curr Opin Infect Dis 2004;17:91-96
15. Nishijima S, Kurokawa I, Nakaya H. Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J Infect Chemother 2002;8: 187-189
16. Nishijima S, Namura S, Mitsuya K, Asada Y. The incidence of isolation of methicillin-resistant Staphylococcus aureus (MRSA) strains from skin infections during the past three years (1989-1991). J Dermatol 1993;20:193-197
17. Silver S. Bacterial silver resistance: Molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev 2003;27:341-353
18. Lansdown AGB. Silver I: its antibacterial properties and mechanism of action. J Wound Care 2002;11:125-130